58 completed, 13 recruiting, 6 unknown, 5 not yet recruiting. 91 Phase 2, 11 Phase 3, 6 Phase 1.
Follow Tuberculosis, Pulmonary: new trials by email Literature Review of Tuberculosis, Pulmonary trials Research Report on Tuberculosis, Pulmonary
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Therapeutic ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB ID93 + GLA-SE vaccine, Placebo vaccine - Tuberculosis, Pulmonary | Phase 2 | Not yet recruiting | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 1500 | 2027-01-31 | 2026-08-24 |
| A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB) Isoniazid, Rifampin, Pyrazinamide - Tuberculosis | Phase 2 | Not yet recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 900 | 2026-10-30 | 2026-08-19 |
| Study of Combinations of Novel Promising Drugs for Pulmonary Tuberculosis TBAJ-587 50 mg, Pretomanid 200mg, Linezolid 600Mg Tab - Tuberculosis, Pulmonary | Phase 2 | Not yet recruiting | TASK Applied Science | 135 | 2026-09-25 | 2026-09-25 |
| AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT Pyrazinamide and Hydroxychloroquine (AI-Optimised), Standard RIPE Regimen (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol) - Pulmonary Tuberculosis | Phase 2 | Not yet recruiting | Ministry of Health, Saudi Arabia | 200 | 2026-09-01 | 2026-03-12 |
| Effects of Adjunct Omega-3 Long Chain Polyunsaturated Fatty Acids in Pulmonary Tuberculosis Patient: an Early Bactericidal Activity and Inflammatory Trial Omega-3 (EPA+DHA), Placebo - Tuberculosis, Inflammation Biomarkers | Phase 2 | Recruiting | North-West University, South Africa | 40 | 2026-08-19 | 2026-09-09 |
| Sorfequiline-based Regimens in Adults With Newly Diagnosed Drug-sensitive Pulmonary TB sorfequiline, Pretomanid, Linezolid - Tuberculosis, Pulmonary | Phase 2 | Recruiting | Global Alliance for TB Drug Development | 100 | 2026-07-09 | 2026-08-19 |
| BRIGHT-Child TB: Short-Course Treatment for Non-Severe Pulmonary Tuberculosis in Children 4-month FDC-based regimen, 3-month BDCZ regimen, Standard 6-month treatment regimen - Tuberculosis | Phase 2 | Recruiting | Huashan Hospital | 90 | 2026-07-08 | 2026-10-26 |
| ATORvastatin in Pulmonary TUBerculosis: a POPulation PharmacoKinetics -PharmacoDynamics Sub-study (ATORTUB popPK-PD) Atorvastatin 20 mg, Atorvastatin 40 mg, Atorvastatin 60 mg - Pulmonary Tuberculosis (TB) | Phase 2 | Recruiting | Obafemi Awolowo University Teaching Hospital | 80 | 2026-01-03 | 2026-01-23 |
| Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis RESP30TB, HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination) - Pulmonary Tuberculoses | Phase 2 | Recruiting | Thirty Respiratory Limited | 24 | 2025-10-13 | 2026-01-12 |
| Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis Bedaquiline, Linezolid, Pretomanid - Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant | Phase 2 / Phase 3 | Recruiting | University of California, San Francisco | 400 | 2025-10-03 | 2026-09-02 |
| Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis Bedaquiline (B), Moxifloxacin, Pyrazinamide (PZA) - Tuberculosis, Pulmonary, Drug-Susceptible Pulmonary Tuberculosis | Phase 2 | Not yet recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 45 | 2025-08-20 | 2025-08-19 |
| Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis Isoniazid, Rifampicin, Pyrazinamide - Pulmonary Tuberculosis | Phase 2 | Suspended | National Institute of Allergy and Infectious Diseases (NIAID) | 341 | 2025-03-11 | 2026-11-02 |
| A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With Ethionamide Alpibectir 45 mg once daily (OD) plus Ethionamide 125 mg OD, Alpibectir 45 mg OD plus Ethionamide 250 mg OD, Isoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight based - Tuberculosis | Phase 2 | Recruiting | TASK Applied Science | 60 | 2025-03-03 | 2025-03-07 |
| Characterization of Tuberculosis Associated Lung Fibrosis and Respiratory Impairment, and Prevention Using Doxycycline Doxycycline, Placebo - Tuberculosis, Pulmonary | Phase 2 | Recruiting | Makerere University | 200 | 2024-12-04 | 2025-04-17 |
| Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB Ganfeborole, BTZ-043, Bedaquiline (B) - Pulmonary Tuberculosis | Phase 2 | Recruiting | University College, London | 2500 | 2024-01-09 | 2026-10-15 |
| ATORvastatin in Pulmonary TUBerculosis Atorvastatin 20mg, Atorvastatin 40mg, Atorvastatin 60mg - Pulmonary Tuberculosis, Tuberculosis | Phase 2 | Recruiting | Obafemi Awolowo University Teaching Hospital | 440 | 2024-01-03 | 2025-09-25 |
| Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible Tuberculosis Bedaquiline (BDQ), Clofazimine (CFZ), Pyrazinamide (PZA) - Tuberculosis, Pulmonary, HIV | Phase 2 | Active not recruiting | Brigham and Women's Hospital | 94 | 2023-11-24 | 2026-08-05 |
| Short-course Regimens for the Treatment of Pulmonary Tuberculosis Rifabutin, Delamanid, Bedaquiline - Tuberculosis, Pulmonary, Tuberculosis Infection | Phase 2 / Phase 3 | Active not recruiting | Centers for Disease Control and Prevention | 288 | 2023-11-21 | 2026-09-21 |
| Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis sorfequiline, Pretomanid, Linezolid - Pulmonary TB, Pulmonary Tuberculosis | Phase 2 | Active not recruiting | Global Alliance for TB Drug Development | 309 | 2023-10-31 | 2026-06-24 |
| BTZ-043 Dose Evaluation in Combination and Selection BTZ-043, Bedaquiline, Delamanid - Tuberculosis, Pulmonary, Other Specified Pulmonary Tuberculosis | Phase 2 | Completed | Michael Hoelscher | 92 | 2023-09-21 | 2026-10-05 |
Showing 20 of 91. Sign in to see all of them.
Tuberculosis (43) · Tuberculosis, Multidrug-Resistant (11) · Extensively Drug-Resistant Tuberculosis (6) · Acquired Immunodeficiency Syndrome (3) · HIV Infections (3) · Gram-Positive Bacterial Infections (2) · Latent Tuberculosis (2) · Communicable Diseases (1) · Infections (1) · Inflammation (1) · Lentivirus Infections (1) · Lung Neoplasms (1) · Mycobacterium Infections (1) · Pneumonia (1)
Actinomycetales Infections (91) · Bacterial Infections (91) · Bacterial Infections and Mycoses (91) · Lung Diseases (91) · Respiratory Tract Diseases (91) · Respiratory Tract Infections (91) · Infections (90) · Mycobacterium Infections (90) · Gram-Positive Bacterial Infections (89) · Tuberculosis (48) · Blood-Borne Infections (5) · Communicable Diseases (5) · Genital Diseases (5) · Immune System Diseases (5) · Immunologic Deficiency Syndromes (5)
Rifampin (32) · Pyrazinamide (30) · Isoniazid (27) · bedaquiline (24) · Ethambutol (22) · pretomanid (20) · Moxifloxacin (19) · Linezolid (15) · OPC-67683 (14) · Clofazimine (7) · 2-(2-methyl-1,4-dioxa-8-azaspiro(4.5)dec-8-yl)-8-nitro-6-(trifluoromethyl)-4H-1,3-benzothiazin-4-one (6) · Protons (6) · Amoxicillin-Potassium Clavulanate Combination (4) · Atorvastatin (4) · GSK656 (4)
Global Alliance for TB Drug Development (11) · National Institute of Allergy and Infectious Diseases (NIAID) (9) · Michael Hoelscher (6) · TASK Applied Science (5) · Centers for Disease Control and Prevention (3) · Medecins Sans Frontieres, Netherlands (3) · National University Hospital, Singapore (3) · Obafemi Awolowo University Teaching Hospital (3) · Otsuka Pharmaceutical Development & Commercialization, Inc. (3) · Archivel Farma S.L. (2) · Gates Medical Research Institute (2) · GlaxoSmithKline (2) · Huashan Hospital (2) · Johns Hopkins University (2) · LigaChem Biosciences, Inc. (2)
South Africa (53) · Uganda (14) · Tanzania (13) · Philippines (11) · Brazil (6) · United States (6) · Vietnam (6) · China (5) · Haiti (5) · India (5) · Peru (5) · Thailand (5) · Georgia (4) · Singapore (4) · South Korea (4)
Andreas Diacon, MD (5) · Rodney Dawson, MD (5) · Bolanle A Omotoso, MD (3) · Kelly Dooley, MD (3) · Nicholas Paton (3) · Andreas Diacon (2) · Clifton E Barry, Ph.D. (2) · Michael Hoelscher, MD (2) · Olanisun O Adewole, MD (2) · Susan Dorman, MD (2) · Adreas Diacon (1) · Andreas Diacon, Prof (1)
PMID 33542052, PMID 36808186, PMID 38768617, PMID 16675781, PMID 22430968, PMID 22670901, PMID 22828481, PMID 22850121, PMID 23075177, PMID 23590701, PMID 25489785, PMID 25622149, PMID 25654354, PMID 25795076, PMID 25880846, PMID 26394045, PMID 28100438, PMID 29528048, PMID 29696707, PMID 29718390, PMID 29973153, PMID 30102705, PMID 31988102, PMID 32381098, PMID 33229425, PMID 33306991, PMID 33374006, PMID 33542056, PMID 33951066, PMID 34252302, PMID 34489274, PMID 34871098, PMID 35258443, PMID 35273049, PMID 35315690, PMID 35366820, PMID 35636648, PMID 35698158, PMID 35876255, PMID 36356989, PMID 36455068, PMID 36546625, PMID 36966799, PMID 37158831, PMID 37280643, PMID 37980911, PMID 38243296, PMID 38365949, PMID 38436463, PMID 38527849
2019 (1), R01AI152142 (1), U01AI134585 (1), U01AI170426 (1), UM1AI068636 (1)